Last reviewed · How we verify
Advagraf
At a glance
| Generic name | Advagraf |
|---|---|
| Also known as | MR4, FK506E, tacrolimus modified release, modified release tacrolimus, tacrolimus |
| Sponsor | Astellas Pharma Korea, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant (PHASE1)
- Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma (PHASE2)
- Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (PHASE1)
- Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf® (PHASE2)
- " SAVE Study (Switch AdVagraf® to Envarsus®) for Fast Metabolizers Kidney Transplant Recipients"
- Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies (PHASE2)
- A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives (PHASE2)
- A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Advagraf CI brief — competitive landscape report
- Advagraf updates RSS · CI watch RSS
- Astellas Pharma Korea, Inc. portfolio CI